Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2014

01-01-2014 | Review Article

Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment

Authors: Christine D. Craig, Bradley J. Monk, John H. Farley, Dana M. Chase

Published in: Supportive Care in Cancer | Issue 1/2014

Login to get access

Abstract

Purpose

To review the etiology and assessment of chemotherapy-related cognitive impairment (CRCI). To explore current treatment and prevention strategies for CRCI and propose future research goals in the field of gynecologic oncology.

Methods

Computerized searches in PubMed of cognitive impairment in cancer between 2000 and 2012 were conducted. The inclusion criteria were randomized control trials evaluating treatment of CRCI and search terms 'cognitive function, cognitive impairment, cognitive decline, chemobrain, chemofog, and cancer'.

Results

To date, numerous modalities have been utilized for assessing CRCI in patients undergoing therapy. It has been proposed to move towards web-based assessment modalities as a possible standard. Few studies have aimed to elucidate possible treatment and prevention options for CRCI; even less in the field of gynecologic oncology. Only seven of these studies were subjected to randomized control trials. Only one of these studies looked at treatment in patients with gynecologic cancers.

Conclusions

The etiology of CRCI is multi-factorial. Following from this, there is no consensus on the best way to assess CRCI although objective measures are more reliable. One must extrapolate data from the non-gynecologic cancer literature, even venturing to non-cancer literature, to explore the treatment and prevention of CRCI. The methods found in these areas of research have not yet been applied to CRCI in gynecologic oncology.
Literature
1.
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice Cognitive Workshop. Ann Oncol 19(4):623–629CrossRefPubMed
2.
Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232CrossRefPubMed
3.
4.
Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192–201CrossRefPubMed
5.
Kurita GP, Sjogren P, Ekholm O et al (2011) Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 29(10):1297–1303CrossRefPubMed
6.
Stavraka C, Ford A, Ghaem-Maghami S et al (2012) A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 125(1):59–64CrossRefPubMed
7.
Reid-Arndt SA (2009) Breast cancer and "chemobrain": the consequences of cognitive difficulties following chemotherapy and the potential for recovery. Mo Med 106(2):127–131PubMed
8.
Burton CL, Strauss E, Hultsch DF, Hunter MA (2006) Cognitive functioning and everyday problem solving in older adults. Clin Neuropsychol 20(3):432–452CrossRefPubMed
9.
Reiriz AB, Reolon GK, Preissler T, et al (2006) Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res;12(16):5000; author reply 5000–1
10.
Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5(7):22CrossRefPubMed
11.
Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7(4):12CrossRefPubMed
12.
Briones TL, Woods J (2011) Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124CrossRefPubMed
13.
Gangloff A, Hsueh WA, Kesner AL et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46(11):1866–1871PubMed
14.
Mayerhofer K, Bodner K, Saletu B et al (2001) Paclitaxel–carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Anticancer Res 21(1B):803–808PubMed
15.
Kreukels BP, Schagen SB, Ridderinkhof KR et al (2006) Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer 7(1):67–78CrossRefPubMed
16.
Cheung YT, Chui WK, Chan A (2012) Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol 83(1):99–111CrossRefPubMed
17.
Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51(2):159–165CrossRefPubMed
18.
Madhyastha S, Somayaji SN, Rao MS, Nalini K, Bairy KL (2002) Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 80(11):1076–1084CrossRefPubMed
19.
Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 30(2):135–148CrossRefPubMed
20.
Aluise CD, Sultana R, Tangpong J et al (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678:147–156PubMed
21.
Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21–27CrossRefPubMed
22.
Pusztai L, Mendoza TR, Reuben JM et al (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94–102CrossRefPubMed
23.
Penson RT, Kronish K, Duan Z et al (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41CrossRefPubMed
24.
Lutgendorf SK, Weinrib AZ, Penedo F et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820–4827CrossRefPubMed
25.
26.
Tangpong J, Sompol P, Vore M et al (2008) Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 151(2):622–629CrossRefPubMed
27.
Tangpong J, Cole MP, Sultana R et al (2006) Adriamycin-induced, TNF-alpha mediated central nervous system toxicity. Neurobiol Dis 23(1):127–139CrossRefPubMed
28.
Joshi G, Sultana R, Tangpong J et al (2005) Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 39(11):1147–1154CrossRefPubMed
29.
Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J (2008) Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 23(3):325–333CrossRefPubMed
30.
Seigers R, Timmermans J, van der Horn HJ et al (2010) Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res 207(2):265–272CrossRefPubMed
31.
Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119(2):366–369CrossRefPubMed
32.
Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). ;14(1):75–9; discussion 79, 81–2, 85
33.
Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21(19):3557–3558CrossRefPubMed
34.
Suri D, Vaidya VA (2012) Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience
35.
Aleman A, Torres-Aleman I (2009) Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 89(3):256–265CrossRefPubMed
36.
Parker WH, Jacoby V, Shoupe D, Rocca W (2009) Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl) 5(5):565–576CrossRefPubMed
37.
Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health (Lond Engl) 5(5):503–516CrossRefPubMed
38.
Loibl S, Lintermans A, Dieudonne AS, Neven P (2011) Management of menopausal symptoms in breast cancer patients. Maturitas 68(2):148–154CrossRefPubMed
39.
Dutta V (2011) Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther 7(3):264–269CrossRefPubMed
40.
Hess LM, Chambers SK, Hatch K et al (2010) Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol 8(6):252–258CrossRefPubMed
41.
Hermelink K, Kuchenhoff H, Untch M et al (2010) Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19(12):1321–1328CrossRefPubMed
42.
Hensley ML, Correa DD, Thaler H et al (2006) Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 102(2):270–277CrossRefPubMed
43.
Deprez S, Amant F, Smeets A et al (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30(3):274–281CrossRefPubMed
44.
Silverman DH, Dy CJ, Castellon SA et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103(3):303–311CrossRefPubMed
45.
Lower EE, Fleishman S, Cooper A et al (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38(5):650–662CrossRefPubMed
46.
Mar Fan HG, Clemons M, Xu W et al (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577–583CrossRefPubMed
47.
Kohli S, Fisher SG, Tra Y et al (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12):2605–2616CrossRefPubMed
48.
Lundorff LE, Jonsson BH, Sjogren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23(8):731–738CrossRefPubMed
49.
O'Shaughnessy JA (2002) Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3(Suppl 3):S116–S120CrossRefPubMed
50.
Fan HG, Park A, Xu W et al (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2):156–161CrossRefPubMed
51.
Jatoi A, Kahanic SP, Frytak S et al (2005) Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 13(1):66–69CrossRefPubMed
52.
Chan KK, Yao TJ, Jones B et al (2011) The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 22(10):2241–2249CrossRefPubMed
53.
Attia A, Rapp SR, Case LD et al (2012) Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol 109(2):357–363CrossRefPubMed
54.
Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210(4):453–469CrossRefPubMed
55.
Raffa RB (2011) Cancer 'survivor-care': I. The alpha7 nAChR as potential target for chemotherapy-related cognitive impairment. J Clin Pharm Ther 36(4):437–445CrossRefPubMed
56.
Speca M, Carlson LE, Goodey E, Angen M (2000) A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 62(5):613–622PubMed
57.
Biegler KA, Chaoul MA, Cohen L (2009) Cancer, cognitive impairment, and meditation. Acta Oncol 48(1):18–26CrossRefPubMed
58.
Oh B, Butow PN, Mullan BA et al (2012) Effect of medical qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 20(6):1235–1242CrossRefPubMed
59.
Cohen K (1999) The way of qigong. 1st trade paperback ed. New York: Ballantine Books; 427
60.
Galantino ML, Greene L, Daniels L, Dooley B, Muscatello L, O'Donnell L (2012) Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series. Explore (NY) 8(2):127–135CrossRefPubMed
61.
Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 220(1):183–193CrossRefPubMed
62.
Ferguson RJ, McDonald BC, Rocque MA et al (2012) Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psychooncology 21(2):176–186CrossRefPubMed
63.
Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 20(12):1251–1258CrossRefPubMed
64.
Mori T, Rezai-Zadeh K, Koyama N et al (2012) Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 287(9):6912–6927CrossRefPubMed
65.
Sattler C, Toro P, Schonknecht P, Schroder J (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196(1):90–95CrossRefPubMed
66.
Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90(3):366–376CrossRefPubMed
67.
Grimmett C, Bridgewater J, Steptoe A, Wardle J (2011) Lifestyle and quality of life in colorectal cancer survivors. Qual Life Res 20(8):1237–1245CrossRefPubMed
68.
Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G (2011) Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44(2):192–201CrossRefPubMed
69.
Hajjar I, Hart M, Chen YL et al (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 172(5):442–444CrossRefPubMed
70.
Brinton LA, Sakoda LC, Frederiksen K et al (2007) Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol 107(3):487–494CrossRefPubMed
71.
Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708CrossRefPubMed
Metadata
Title
Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment
Authors
Christine D. Craig
Bradley J. Monk
John H. Farley
Dana M. Chase
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2029-7

Other articles of this Issue 1/2014

Supportive Care in Cancer 1/2014 Go to the issue

Original Article

The multiple oral presentations of multiple myeloma

Original Article

Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up

Letter to the editor

Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?

Original Article

What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups

Original Article

Development and validation of a prognostic scale for hospitalized patients with terminally ill cancer in China

Original Article

Antiemetic prescribing practices using a computerized physician order entry system
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits